Form 4: Inmune Bio Director Marcia Allen Reports Stock Option Grant

Director Marcia Allen reports receiving a stock option grant from Inmune Bio, Inc.

Summary

• On May 16, 2024, Marcia Allen, a director of Inmune Bio, Inc., filed a Form 4 with the SEC.
• The form reports a transaction that occurred on May 14, 2024, where Allen was granted an option to buy 12,500 shares of Inmune Bio common stock at an exercise price of $9.92.
• The options were granted pursuant to the 2021 Stock Incentive Plan and will vest monthly over one year, becoming fully vested on the one-year anniversary of the grant date.
• Following the transaction, Allen directly owns 12,500 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grant. It's a standard practice for incentivizing directors.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing her to work towards increasing the company's stock value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders' equity if the options are exercised.

Key Dates